IBTA
@theIBTA
Followers
5K
Following
4K
Media
287
Statuses
8K
The IBTA is an alliance of the support, advocacy and information groups for brain tumour patients and carers around the world.
Joined May 2011
The official report on the International Patient Advocacy Symposium on Brain Metastases is available here: https://t.co/H3BKQTqF1u
#brainmetastases #brainmets #braintumour
0
3
10
The IBTA e-News Roundup for September/October 2025 -
mailchi.mp
Click here to read our monthly roundup on all the latest brain tumour news and developments.
0
0
0
Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
gov.uk
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).
0
0
2
The IBTA e-News Roundup for August 2025 -
mailchi.mp
Click here to read our monthly roundup on all the latest brain tumour news and developments.
0
0
1
Proton Therapy Benefits IDH-Mutant Glioma Patients
oncodaily.com
New RT Paper Alert: Proton Therapy Benefits IDH-Mutant Glioma Patients / brain tumors, cancer, IDH-mutant glioma, OncoDaily, Oncology, radiation oncology,
0
0
1
The IBTA e-News Roundup for July 2025 -
mailchi.mp
Click here to read our monthly roundup on all the latest brain tumour news and developments.
0
0
0
Glioblastoma Funding Rises as Nonprofits Drive Interest and Pharma Returns to the Table
biospace.com
After decades of limited progress—owing to the difficulty of treating the disease and resultant market risk—glioblastoma research is entering a new phase spurred by smarter trials, targeted funding...
0
0
2
Servier Receives Positive CHMP Opinion for VORANIGO® (vorasidenib) for the Treatment of Adults and Adolescents with Grade 2 IDH-mutant Diffuse Glioma https://t.co/NSaYkpUmzm
servier.mediaroom.com
Recommendation is based on positive results from the pivotal Phase 3 INDIGO trial of VORANIGO If approved, VORANIGO would be the first and only targeted therapy for Grade 2 IDH-mutant glioma in the EU
0
3
5
The IBTA e-News Roundup for June 2025 -
mailchi.mp
Click here to read our monthly roundup on all the latest brain tumour news and developments.
0
0
0
Machine learning can improve detection of brain cancer from blood
source.washu.edu
Neurosurgeon Dimitrios Mathios, MD, at Washington University School of Medicine in St. Louis, has developed a liquid biopsy that is aided by machine-learning tools to improve the detection of brain...
0
0
0
The IBTA e-News Roundup for May 2025 -
mailchi.mp
Click here to read our monthly roundup on all the latest brain tumour news and developments.
0
0
0
Could electric fields supercharge immune attack on the deadliest form of brain cancer?
news.keckmedicine.org
LOS ANGELES — A new study led by Keck Medicine of USC researchers may have uncovered an effective combination therapy for glioblastoma, a brain tumor diagnosis with few available effective treatmen...
0
1
1
Our thoughts are with the loved ones of Dr Stu Farrimond, who has sadly passed away. We are so grateful for everything he did to raise awareness of this cruel disease & fight for better outcomes for those affected. @theIBTA #BrainTumourResearch #TogetherWeWillFindACure
0
4
19
The GLIORESOLVE project was featured in the 2024/2025 World Edition of the Brain Tumour Magazine, published by the @theIBTA You can read the full publication here https://t.co/kXO0k0q8zX and our article is on Pg 23!
issuu.com
The fourteenth annual edition of the official magazine of the International Brain Tumour Alliance (IBTA).
0
2
3
The IBTA e-News Roundup for January/February 2025 -
mailchi.mp
Click here to read our monthly roundup on all the latest brain tumour news and developments.
0
0
1
The #EUCancerPlan has been a success for member states, yet so much remains to be done. 👈 Inequalities in reach and accessibility of cancer care persist. The solution: concrete, data-driven insights to drive robust policy action. 📈 The #EuropeanCancerPulse provides vital
0
5
11
🚀 We are proud to announce that @sisaqol final recommendations are here! 🎗️This global initiative, co-led by EORTC & @Boehringer, sets new standards for analysing patient-reported outcomes in cancer trials. Learn more: https://t.co/XNXDq28ZmN
#CancerResearch #QualityofLife
eortc.org
EORTC announces the public launch of SISAQOL-IMI, an initiative aimed at standardising the analysis of patient-reported outcomes (PROs).
📢 Yesterday, SISAQOL-IMI officially launched its final recommendations for standardising patient-reported outcomes in cancer clinical trials! 🎉 A huge step toward better, more reliable data for patient-centered care. Learn more:
0
4
11